Posted by Michael Wonder on 24 Apr 2020
FDA approves MenQuadfi, the latest innovation in meningococcal (MenACWY) vaccination
24 April 2020 - Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
The U.S. FDA has approved a biologics license application for MenQuadfi Meningococcal (Groups A, C, Y, W) conjugate vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older.
MenQuadfi was designed to elicit and demonstrated a high immune response across all four serogroups for multiple ages and was well tolerated. MenQuadfi is intended to protect an expanded age group. Licensure marks MenQuadfi as the only U.S. FDA approved quadrivalent meningococcal vaccine indicated for persons 2 through 56 years of age and older.
